Familial Adenomatous Polyposis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Familial adenomatous polyposis (FAP) or classic FAP is a genetic condition that causes extra tissue (polyps) to form in large intestine and rectum. It is caused by germline mutations in the APC gene. Symptoms include blood or mucus in the stools, diarrhea or constipation, weight loss due to unknown reason and abdominal pain. Treatment includes surgery and medications (NSAIDs).
The Familial Adenomatous Polyposis – Drugs In Development research report provides a comprehensive overview on the therapeutics under development for Familial Adenomatous Polyposis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Familial Adenomatous Polyposis and features dormant and discontinued projects.
Key Targets in the Familial Adenomatous Polyposis Pipeline Drugs Market
The key targets in the Familial Adenomatous Polyposis pipeline drugs market are Ornithine Decarboxylase, Casein Kinase I Isoform Alpha, Collagen Alpha 1(VII) Chain, Interleukin 10 Receptor, and Janus Kinase among others.
Familial Adenomatous Polyposis Drugs Market, by Targets
For more target insights, download a free report sample
Key MoA in the Familial Adenomatous Polyposis Pipeline Drugs Market
The key mechanisms of action in the Familial Adenomatous Polyposis pipeline drugs market are Ornithine Decarboxylase Inhibitor, Casein Kinase I Isoform Alpha Activator, Collagen Alpha 1(VII) Chain Activator, Janus Kinase Inhibitor, and Interleukin 10 Receptor Agonist.
Familial Adenomatous Polyposis Pipeline Drugs Market, by MoA
To get more insights on key MoA, download a free sample report
Familial Adenomatous Polyposis Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Familial Adenomatous Polyposis pipeline drugs market are Subcutaneous, Intravenous, Oral, and Intradermal.
Familial Adenomatous Polyposis Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Familial Adenomatous Polyposis Pipeline Drugs Market
The key molecule types in the Familial Adenomatous Polyposis pipeline drugs market are Monoclonal Antibody, Small Molecule, Recombinant Protein, Gene Therapy, Synthetic Peptide, Protein and Subunit Vaccine among others.
Familial Adenomatous Polyposis Pipeline Drugs Market, by Molecule Type
To get more insights on key molecule types, download a free sample report
Major Companies in the Familial Adenomatous Polyposis Pipeline Drugs Market
The major companies in the Familial Adenomatous Polyposis pipeline drugs market are Cancer Prevention Pharmaceuticals Inc, ADT Pharmaceuticals Inc, Cellix Bio Pvt Ltd, DNAlite Therapeutics Inc, and Eloxx Pharmaceuticals Inc among others.
Familial Adenomatous Polyposis Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Familial Adenomatous Polyposis Pipeline Drugs Market Overview
Key Targets | Ornithine Decarboxylase, Casein Kinase I Isoform Alpha, Collagen Alpha 1(VII) Chain, Interleukin 10 Receptor, and Janus Kinase among others. |
Key Mechanisms of action | Ornithine Decarboxylase Inhibitor, Casein Kinase I Isoform Alpha Activator, Collagen Alpha 1(VII) Chain Activator, Janus Kinase Inhibitor, and Interleukin 10 Receptor Agonist
|
Key Routes of Administration | Subcutaneous, Intravenous, Oral, and Intradermal |
Key molecule types | Monoclonal Antibody, Small Molecule, Recombinant Protein, Gene Therapy, Synthetic Peptide, Protein and Subunit Vaccine |
Major companies | Cancer Prevention Pharmaceuticals Inc, ADT Pharmaceuticals Inc, Cellix Bio Pvt Ltd, DNAlite Therapeutics Inc, and Eloxx Pharmaceuticals Inc among others. |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Familial Adenomatous Polyposis
- The pipeline guide reviews pipeline therapeutics for Familial Adenomatous Polyposis by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Familial Adenomatous Polyposis therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Familial Adenomatous Polyposis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Familial Adenomatous Polyposis
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Familial Adenomatous Polyposis
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Familial Adenomatous Polyposis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Cancer Prevention Pharmaceuticals Inc
Cellix Bio Pvt Ltd
DNAlite Therapeutics Inc
Eloxx Pharmaceuticals Inc
Emtora Biosciences
FunPep Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
KD Pharma Group SA
Recursion Pharmaceuticals Inc
SanaRx Biotherapeutics Inc
Stemsynergy Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
TherapyX Inc
Thetis Pharmaceuticals LLC
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Familial Adenomatous Polyposis pipeline drugs market?
The key targets in the Familial Adenomatous Polyposis pipeline drugs market are Ornithine Decarboxylase, Casein Kinase I Isoform Alpha, Collagen Alpha 1(VII) Chain, Interleukin 10 Receptor, and Janus Kinase among others.
-
What are the key mechanisms of action in the Familial Adenomatous Polyposis pipeline drugs market?
The key mechanisms of action in the Familial Adenomatous Polyposis pipeline drugs market are Ornithine Decarboxylase Inhibitor, Casein Kinase I Isoform Alpha Activator, Collagen Alpha 1(VII) Chain Activator, Janus Kinase Inhibitor, and Interleukin 10 Receptor Agonist.
-
What are the key routes of administration in the Familial Adenomatous Polyposis pipeline drugs market?
The key routes of administration in the Familial Adenomatous Polyposis pipeline drugs market are Subcutaneous, Intravenous, Oral, and Intradermal.
-
What are the key molecule types in the Familial Adenomatous Polyposis pipeline drugs market?
The key molecule types in the Familial Adenomatous Polyposis pipeline drugs market are Monoclonal Antibody, Small Molecule, Recombinant Protein, Gene Therapy, Synthetic Peptide, Protein and Subunit Vaccine among others.
-
What are the major companies in the Familial Adenomatous Polyposis pipeline drugs market?
The major companies in the Familial Adenomatous Polyposis pipeline drugs market are Cancer Prevention Pharmaceuticals Inc, ADT Pharmaceuticals Inc, Cellix Bio Pvt Ltd, DNAlite Therapeutics Inc, and Eloxx Pharmaceuticals Inc among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.